Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients

AUTOR(ES)

Cury, Priscilla Cury de Camargo; Higashi, Fabiana; Zacchi, Flávia Fernandes Silva; Palhares, Renata Bacic; Quero, Adriana Alvares; Dias, Ana Luiza Miranda Silva; Crusoé, Edvan de Queiroz; Hungria, Vania Tietsche de Moraes

FONTE

Hematol., Transfus. Cell Ther.

DATA DE PUBLICAÇÃO

2020-06

RESUMO

ABSTRACT Background: Bone marrow angiogenesis is increased in multiple myeloma (MM) patients, prompting the rationale for using antiangiogenic drugs in the treatment of these patients. Objective: To assess angiogenesis in patients with MM at diagnosis and following treatment with an antiangiogenic drug. Patients and Methods: Twenty-three patients with newly diagnosed MM were treated with thalidomide-based regimens. Bone marrow evaluation was made before and following treatment and included angiogenesis assessment, which was quantified through microvessel density (MVD) determination, by means of anti-CD34 immunohistochemical labeling, and classified either as high MVD or low MVD, according to the mean CD34 count: above or below the median of 12.6. Results: The pre-therapy median MVD was 12 (7.5-18.3) versus 8.7 (5.35-18.5) post-therapy, p = 0.2114. Conclusions: Our study found no reduction in MVD before and following treatment and, accordingly, we could establish no relationship between MVD and response to therapy in the sample we studied.

Documentos Relacionados

• Multiple myeloma with bone marrow extracellular crystal deposition
• The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
• Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
• Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
• Observations on the Mechanism of Bone Resorption Induced by Multiple Myeloma Marrow Culture Fluids and Partially Purified Osteoclast-activating Factor